Abstract
Original language | English |
---|---|
Pages (from-to) | 327-353 |
Number of pages | 27 |
Journal | Radiotherapy and oncology |
Volume | 154 |
DOIs | |
Publication status | Published - 1 Jan 2021 |
Keywords
- Endometrial carcinoma
- Guidelines
- Management
- Molecular markers
- Staging
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Radiotherapy and oncology, Vol. 154, 01.01.2021, p. 327-353.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
AU - Concin, Nicole
AU - Matias-Guiu, Xavier
AU - Vergote, Ignace
AU - Cibula, David
AU - Mirza, Mansoor Raza
AU - Marnitz, Simone
AU - Ledermann, Jonathan
AU - Bosse, Tjalling
AU - Chargari, Cyrus
AU - Fagotti, Anna
AU - Fotopoulou, Christina
AU - Martin, Antonio Gonzalez
AU - Lax, Sigurd
AU - Lorusso, Domenica
AU - Marth, Christian
AU - Morice, Philippe
AU - Nout, Remi A.
AU - O'Donnell, Dearbhaile
AU - Querleu, Denis
AU - Raspollini, Maria Rosaria
AU - Sehouli, Jalid
AU - Sturdza, Alina
AU - Taylor, Alexandra
AU - Westermann, Anneke
AU - Wimberger, Pauline
AU - Colombo, Nicoletta
AU - Planchamp, François
AU - Creutzberg, Carien L.
N1 - Funding Information: The authors thank ESGO, ESTRO, and ESP for their support. ESGO office, especially Kamila Macku, provided invaluable logistical and administrative support throughout the process. The authors also thank the 191 international reviewers (physicians and patient representatives, Appendix 2) for their valuable comments and suggestions. The European Society for Medical Oncology, Professor Cristiana Sessa and the ESMO-ESGO-ESTRO consensus conference working group are gratefully acknowledged for the previous 2014 Endometrial Consensus Conference. The authors wish to express sincere gratitude to Annette Hasenburg and Joachim Weis for describing the psycho-oncological aspects in this article. All costs relating to the development process were covered from ESGO, ESTRO, and ESP funds. There was no external funding of the development process or manuscript production. NCon has reported advisory boards for Seattle Genetics, AstraZeneca and Mersana, education fees from Medscape Oncology, and grants for travelling from Roche, Genmab and Amgen; IV has reported advisory boards for Amgen, AstraZeneca, Clovis Oncology, Carrick Therapeutics, Debiopharm International, F. Hoffmann-La Roche, Genmab, GSK, Immunogen, Millenium Pharmaceuticals, MSD Belgium, Octimet Oncology, Oncoinvent, Pharmamar-Doctaforum Servicios, Roche, Sotio a.s. Tesaro, Deciphera Pharmaceuticals and Verastem Oncology (fees for consulting to his university), contracted research (KU Leuven) for Oncoinvent AS and Genmab, corporate sponsored research for Amgen and Roche, and grants for travelling from Amgen, MSD/Merck, Roche, AstraZeneca and Tesaro; DC has reported advisory boards for AstraZeneca, Roche, Sotio and Novocure; MRM has reported personal financial interests for AstraZeneca, Biocard, Clovis Oncology, Geneos, Genmab, Karyopharm Therapeutics, Merck, Mersana, MSD, Oncology Venture, Pfizer, Roche, SeatleGenetics, SeraPrognostics, Sotio, Tesaro-GSK, ZaiLab, leadership role for Karyopharm Therapeutics Inc. Sera Prognostics Inc. and institutional financial interests (study grants)forAstraZeneca, Boehringer Ingelheim, Clovis Oncology, Pfizer, Tesaro-GSK, Ultimovacs; JL has reported advisory boards for AstraZeneca, Pfizer, GSK, Eisai, MSD/Merck, Artios Pharma, Regeneron, Amgen and Clovis Oncology, and grants for travelling from Clovis Oncology; CC has reported advisory boards for MSD, Takeda and GSK, conducting research for TherAguiX and Roche, and grants for travelling from Takeda; AF has reported advisory boards for GSK and Johnson & Johnson SpA, and grants for travelling from Pharmmar and MSD Italia; CF has reported advisory boards for AstraZeneca, Clovis, Ethicon, Roche, MSD, GSK and Tesaro, and grants fro travelling from Sequana; AGM has reported speakers? bureau activities for AstraZeneca, Pharmamar, Roche and GSK, advisory boards for Amgen, AstraZeneca, Clovis Oncology, genmab, GSK, Immunogen, Merck Sharp & Dohme, Novartis, Oncoinvent, Pfizer/Merck, Pharmamar, Roche and Sotio, and grants for travelling from AstraZeneca, Pharmamar Roche and Tesaro; DL has reported advisory boards for Roche, Amgen, MSD, GSK, Clovis, AstraZeneca, Immunogen, Genmab, Pharmamar and Merck, and grants for travelling from Pharmamar, GSK, Roche and AstraZeneca; CM has reported consulting/advisory boards for Roche, Novartis, Amgen, MSD, AstraZeneca, Pfizer, Pharmamar, Cerulean, Vertex and Tesaro, funded research from EU, FWF, AstraZeneca and Roche, and honoraria/expenses from Roche, Novartis, Amgen, MSD, Pharmamar, AstraZeneca and Tesaro; JS has reported advisory boards for Roche, Eisei, MSD, AstraZeneca, Clovis, GSK and Tesaro; AT has reported advisory boards for Genmab; PW has reported advisory boards for Amgen, AstraZeneca, MSD, Novartis, Pfizer, Pharmamar, Lilly, Roche Pharma GmbH, TEVA, Eisai, Clovis and Tesaro, and grants for travelling from Roche Pharma GmbH, AstraZeneca, MSD, Amgen and Pfizer; NC has reported consulting and advisory services, speaking or writing engagements, public presentations for Roche, AstraZeneca, MSD, Pharmamar, Tesaro, GSK, Clovis, Advaxis, Pfizer, Takeda, Immunogen, Biocad, Amgen, Novartis and Ellipses, institutional financial interests for Roche, Pharmamar and AstraZeneca, and non-financial interests for ESMO clinical Guidelines (subject editor for gynecological cancer); XMG, SM, TB, SL, PM, RN, DOD, DQ, MRR, AS, AW, FP and CLC have reported no conflicts of interest. Publisher Copyright: © 2021 International Gynecologic Cancer Society and European Society of Gynecological Oncology [Published by BMJ]; Springer Verlag GmbH Berlin Heidelberg, part of Springer Nature Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (27 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2014, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 191 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover endometrial carcinoma staging, definition of prognostic risk groups integrating molecular markers, pre- and intra-operative work-up, fertility preservation, management for early, advanced, metastatic, and recurrent disease and palliative treatment. Principles of radiotherapy and pathological evaluation are also defined.
AB - A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (27 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2014, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 191 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover endometrial carcinoma staging, definition of prognostic risk groups integrating molecular markers, pre- and intra-operative work-up, fertility preservation, management for early, advanced, metastatic, and recurrent disease and palliative treatment. Principles of radiotherapy and pathological evaluation are also defined.
KW - Endometrial carcinoma
KW - Guidelines
KW - Management
KW - Molecular markers
KW - Staging
UR - http://www.scopus.com/inward/record.url?scp=85102916477&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.radonc.2020.11.018
DO - https://doi.org/10.1016/j.radonc.2020.11.018
M3 - Article
C2 - 33712263
SN - 0167-8140
VL - 154
SP - 327
EP - 353
JO - Radiotherapy and oncology
JF - Radiotherapy and oncology
ER -